Country

Clinical trials in South Korea

Active obesity and GLP-1 studies with at least one location in South Korea.

21active studies

11recruiting now

20countries represented

70largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

NNC0662-0419, SemaglutideTreatment

Croatia, Hungary63 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07415954See eligibility →

Recruiting nowNot applicable

Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery

Gastric Cancer, Diabetes Mellitus, Type 2Condition

Long limb Roux-en-Y reconstruction after subtotal gastrectomy, Conventional Roux-en-Y reconstruction after subtotal gastrectomyTreatment

South Korea1 locations

Korea University Anam HospitalSponsor

Updated 2026-08-07 · NCT04284943See eligibility →

Recruiting nowNot applicable

Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies

Food Addiction Tendency, ObesityCondition

SemaglutideTreatment

South Korea1 locations

Seoul National University HospitalSponsor

Updated 2026-07-28 · NCT07732426See eligibility →

Recruiting nowPhase 1

A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

Obesity & Overweight, Type 2 DiabetesCondition

DWRX5003, DWC202502Treatment

South Korea1 locations

Daewoong Pharmaceutical Co. LTD.Sponsor

Updated 2026-07-16 · NCT07539415See eligibility →

Recruiting nowPhase 2

Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients

Overweight, ObesityCondition

KDS2010, KDS2010Treatment

South Korea3 locations

NeuroBiogen Co., LtdSponsor

Updated 2026-06-24 · NCT07009171See eligibility →

Recruiting nowPhase 4

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

Obesity and Type 2 DiabetesCondition

Enavogliflozin, PlaceboTreatment

South Korea1 locations

Korea University Anam HospitalSponsor

Updated 2025-09-02 · NCT06782139See eligibility →

Recruiting nowNot applicable

Dual-chamber Patient-controlled Analgesia for Postoperative Recovery

Morbid Obesity, PCACondition

multimodal analgesia via dual-chamber PCA, single regimen (only fentanyl)Treatment

South Korea1 locations

Seoul National University Bundang HospitalSponsor

Updated 2025-07-03 · NCT07051109See eligibility →

Recruiting nowNot applicable

Electrosurgical Bipolar Systems Versus Conventional Electrocautery After SLNBx

Breast CancerCondition

Electrosurgical bipolar system (LigaSure)Treatment

South Korea1 locations

SMG-SNU Boramae Medical CenterSponsor

Updated 2024-05-23 · NCT06426810See eligibility →

Recruiting nowNot applicable

Nutriomics and Artificial Intelligence Nutrition Obesity Cohort

ObesityCondition

Intervention not listedTreatment

South Korea1 locations

Yonsei UniversitySponsor

Updated 2022-08-09 · NCT05494138See eligibility →

Opening soonPhase 3

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

Obesity, OverweightCondition

Zenagamtide, Placebo ( matched to Zenagamtide)Treatment

India, Japan44 locations

Novo Nordisk A/SSponsor

Updated 2026-08-24 · NCT07668401See eligibility →

Opening soonNot applicable

Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)

Obesity, Metabolic SyndromeCondition

Semaglutide (Wegovy®), ¹⁸FDG-PET/CT with cold stimulationTreatment

South Korea2 locations

Hallym UniversitySponsor

Updated 2026-07-22 · NCT07621640See eligibility →

Invitation onlyNot applicable

The Efficacy and Safety of Herbal Medicine Treatment for Obese Patients With Spinal and Joint Pain

Obesity and OverweightCondition

Herbal medicine treatment, Life GuidanceTreatment

South Korea1 locations

Jaseng Medical FoundationSponsor

Updated 2026-07-02 · NCT06859697See eligibility →

Invitation onlyNot applicable

Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study

Diabetes Mellitus, Type 2, ObesityCondition

No treatment givenTreatment

South Korea1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-29 · NCT07673822See eligibility →

Invitation onlyNot applicable

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes Mellitus, Type 2Condition

SemaglutideTreatment

South Korea1 locations

Novo Nordisk A/SSponsor

Updated 2026-05-05 · NCT05689372See eligibility →

Invitation onlyNot applicable

WEgovy Real World Assessment of Weight Loss in Korea

ObesityCondition

SemaglutideTreatment

South Korea1 locations

Novo Nordisk A/SSponsor

Updated 2025-12-12 · NCT07280221See eligibility →

Invitation onlyNot applicable

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

Obesity and OverweightCondition

semaglutideTreatment

South Korea8 locations

Novo Nordisk A/SSponsor

Updated 2025-06-12 · NCT07018544See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Overweight, ObesityCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

Argentina, Canada67 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07220759See eligibility →

Active, not recruitingNot applicable

Postoperative Gastroesophageal Reflux Symptoms After Laparoscopic Sleeve Gastrectomy Based on the Presence of Preoperative Symptoms

Obesity and Obesity-related Medical Conditions, Laparoscopic Sleeve GastrectomyCondition

Laparoscopic sleeve gastrectomyTreatment

South Korea1 locations

Korea University Anam HospitalSponsor

Updated 2025-09-05 · NCT06835933See eligibility →

Active, not recruitingPhase 2

Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes MellitusCondition

PG-102, PlaceboTreatment

South Korea14 locations

ProGen. Co., Ltd.Sponsor

Updated 2025-07-11 · NCT06712615See eligibility →

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.